Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping 85% off the share price of the beleaguered biotech. The phase 3 ...

Kia has officially revealed the name of its upcoming compact SUV and contrary to previous reports, it will be called “Syros”. Although Kia did file a trademark application for the “Syros ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC. Syros Pharmaceuticals on Tuesday ...

SEC Filings provided by EDGAR Online, Inc.

Your browser does not support the audio element. Kia has announced that its upcoming compact SUV will be called the Syros. Internally codenamed the AY, the Kia Syros ...

Q ) What is the expected price of Kia Syros? A ) The price of Kia Syros is expected to be Rs. 6 Lakh *. Q ) What is the estimated launch date of Kia Syros? A ) The estimated launch date of Kia ...

These vehicles have strengthened Kia's presence in India's premium market. Now, with the Syros, Kia is poised to make a significant impact in the mass-market SUV segment. The Syros is expected to ...

Kia has officially confirmed the name of its upcoming SUV and it is called the Syros in India. The Syros would be the Kia 2.0 SUV and is a sub compact SUV which will slot below the Seltos while being ...

Kia claims that the Syros will feature a unique and progressive SUV design language that doesn’t follow the conventional SUV design anymore.

Kia will expand its crossover lineup in India with a new offering called Syros. The model will reportedly arrive in 2025, offering ICE and EV powertrain options. The teaser reveals a minivan ...